<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956044</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1442-C-453</org_study_id>
    <nct_id>NCT02956044</nct_id>
  </id_info>
  <brief_title>Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin</brief_title>
  <official_title>A Phase 1, Open-label, Randomized, Three-period, Crossover Study to Evaluate Pharmacokinetic Interaction Between Bexagliflozin Tablets and Metformin, Glimepiride, or Sitagliptin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the drug-drug interaction in your body when given the&#xD;
      study drug, bexagliflozin, with three commonly used ant-diabetic medications, metformin,&#xD;
      glimepiride or sitagliptin. The study will also evaluate how safe the study drug is and how&#xD;
      well the study drug is tolerated when taken with metformin, glimepiride or sitagliptin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 54 healthy subjects were enrolled and assigned to one of three groups of eighteen.&#xD;
      Each group participated in one of three open-label, randomized, three treatment period,&#xD;
      crossover studies:&#xD;
&#xD;
        -  Group 1: Bexagliflozin/metformin drug-drug interaction (DDI)&#xD;
&#xD;
        -  Group 2: Bexagliflozin/glimepiride DDI&#xD;
&#xD;
        -  Group 3: Bexagliflozin/sitagliptin DDI For each Group, every subject received a single&#xD;
           dose of bexagliflozin tablet, 20 mg, alone, a single dose of an oral hypoglycemic agent&#xD;
           (OHA) (1000 mg metformin, 2 mg glimepiride, or 100 mg sitagliptin) alone, and the&#xD;
           combination of both (bexagliflozin tablet and OHA) alternately in a crossover fashion,&#xD;
           with three treatment periods separated by a washout period of at least 7 days. Within&#xD;
           each Group, subjects were randomized to one of six treatment sequences in an equal&#xD;
           ratio.&#xD;
&#xD;
      To prevent hypoglycemia, subjects assigned to Group 2 (bexagliflozin/glimepiride DDI)&#xD;
      received approximately 300 mL of a solution containing 50 g of glucose with study medication&#xD;
      at the time of dosing, as well as approximately 75 mL of a solution containing 12.5 g of&#xD;
      glucose every 15 minutes for 4 hours post-dose.&#xD;
&#xD;
      For each treatment period in Group 1 (bexagliflozin/metformin DDI) and Group 2&#xD;
      (bexagliflozin/glimepiride DDI), subjects were admitted to the clinic on the day before&#xD;
      dosing and stayed in the clinic until 48 h post-dose. For Group 3 (bexagliflozin/sitagliptin&#xD;
      DDI), subjects stayed in the clinic until 72 h post-dose.&#xD;
&#xD;
      For all Groups, blood samples for PK analysis were collected in each period prior to dosing&#xD;
      (pre-dose) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose. For Group&#xD;
      3, PK blood samples were also collected at 60 and 72 h post-dose. Plasma concentrations of&#xD;
      bexagliflozin and OHAs were determined by validated liquid chromatography tandem mass&#xD;
      spectrometry (LC MS/MS) assays.&#xD;
&#xD;
      Urine samples for PD analysis were collected in 12 h intervals. For all Groups, urine samples&#xD;
      were collected pre-dose (-12 to 0 h) and post-dose at 0 to 12 h, 12 to 24 h, 24 to 36 h, and&#xD;
      36 to 48 h. For Group 3, additional samples at 48 to 60 h and 60 to 72 h post-dose were&#xD;
      collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum Observed Plasma Concentration)</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Cmax was obtained directly from experimental observations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (Time of Maximum Observed Plasma Concentration)</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Tmax was obtained directly from experimental observations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 (Apparent Terminal Elimination Half-life)</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. T1/2 was obtained directly from experimental observations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. AUC0-inf was estimated for each subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Glucose Excretion up to 0-72 hr</measure>
    <time_frame>up to 0-72 hr</time_frame>
    <description>Pre-dose urine samples were collected from -12 to 0 h for baseline measurement. Subjects was instructed to empty their bladder prior to dosing. Post-dose urine was collected in 4 batches for Groups 1 and 2 at 0 to 12 h, 12 to 24 h, 24 o 36 h, and 36 to 48 h collections. Post-dose urine was collected in batches for Group 3 at 0 to 12 h, 12 to 24 h, 24 to 36 h, 36 to 48 h, 48 to 60 h and 60 to 72 h.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group 1: Bexagliflozin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Metformin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Bexagliflozin + Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Bexagliflozin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Glimepiride alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Bexagliflozin + Glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Bexagliflozin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Sitagliptin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Bexagliflozin + Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexagliflozin</intervention_name>
    <description>Bexagliflozin tablets, 20 mg</description>
    <arm_group_label>Group 1: Bexagliflozin + Metformin</arm_group_label>
    <arm_group_label>Group 1: Bexagliflozin alone</arm_group_label>
    <arm_group_label>Group 2: Bexagliflozin + Glimepiride</arm_group_label>
    <arm_group_label>Group 2: Bexagliflozin alone</arm_group_label>
    <arm_group_label>Group 3: Bexagliflozin + Sitagliptin</arm_group_label>
    <arm_group_label>Group 3: Bexagliflozin alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>1000 mg metformin</description>
    <arm_group_label>Group 1: Bexagliflozin + Metformin</arm_group_label>
    <arm_group_label>Group 1: Metformin alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>4 mg glimepiride</description>
    <arm_group_label>Group 2: Bexagliflozin + Glimepiride</arm_group_label>
    <arm_group_label>Group 2: Glimepiride alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100 mg sitagliptin</description>
    <arm_group_label>Group 3: Bexagliflozin + Sitagliptin</arm_group_label>
    <arm_group_label>Group 3: Sitagliptin alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2&#xD;
&#xD;
          2. Subjects who are non-smokers for at least 3 months prior to screening&#xD;
&#xD;
          3. Subjects who are willing and able to be confined to the clinical research facility as&#xD;
             required by the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a clinically significant history of allergy to drugs or latex.&#xD;
&#xD;
          2. Subjects with a history of alcohol or drug dependence in the past 12 months.&#xD;
&#xD;
          3. Subjects who have donated a significant amount of blood in the past 2 months&#xD;
&#xD;
          4. Female subjects who are pregnant or breastfeeding&#xD;
&#xD;
          5. Subjects who are not willing to use an adequate form of birth control during the study&#xD;
             and for 30 days after discharge from clinic&#xD;
&#xD;
          6. Subjects who have taken an investigational drug in the past 30 days or 7 half-lives of&#xD;
             the investigational drug, whichever is longer&#xD;
&#xD;
          7. Subjects who had previously received anti-diabetic medication, including metformin,&#xD;
             sitagliptin, glimepiride or drugs of the same class (i.e. biguanides, DPP-4 inhibitors&#xD;
             or sulfonylureas), or SGLT2 inhibitors, in the past 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mason Freeman, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <results_first_submitted>May 21, 2021</results_first_submitted>
  <results_first_submitted_qc>July 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 22, 2021</results_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Bexagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02956044/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02956044/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Bexagliflozin + Metformin</title>
          <description>Bexagliflozin tablets 20 mg alone, Metformin tablets 1000 mg alone, or Bexagliflozin 20 mg + Metformin 1000 mg</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Bexagliflozin + Glimepiride</title>
          <description>Bexagliflozin tablets 20 mg alone, Glimepiride tablets 2 mg alone, or Bexagliflozin 20 mg + Glimepiride 2 mg</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Bexagliflozin + Sitagliptin</title>
          <description>Bexagliflozin tablets 20 mg alone, Sitagliptin 100 mg alone, or Bexagliflozin 20 mg + Sitagliptin 100 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Bexagliflozin + Metformin</title>
          <description>Bexagliflozin tablets 20 mg alone, Metformin tablets 1000 mg alone, or Bexagliflozin 20 mg + Metformin 1000 mg</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Bexagliflozin + Glimepiride</title>
          <description>Bexagliflozin tablets 20 mg alone, Glimepiride tablets 2 mg alone, or Bexagliflozin 20 mg + Glimepiride 2 mg</description>
        </group>
        <group group_id="B3">
          <title>Group 3: Bexagliflozin + Sitagliptin</title>
          <description>Bexagliflozin tablets 20 mg alone, Sitagliptin 100 mg alone, or Bexagliflozin 20 mg + Sitagliptin 100 mg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" spread="15.69"/>
                    <measurement group_id="B2" value="37.6" spread="8.25"/>
                    <measurement group_id="B3" value="43.6" spread="14.52"/>
                    <measurement group_id="B4" value="41.1" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.0" spread="11.75"/>
                    <measurement group_id="B2" value="77.9" spread="12.37"/>
                    <measurement group_id="B3" value="79.0" spread="13.21"/>
                    <measurement group_id="B4" value="78.6" spread="12.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173.3" spread="9.16"/>
                    <measurement group_id="B2" value="172.3" spread="6.45"/>
                    <measurement group_id="B3" value="170.5" spread="8.37"/>
                    <measurement group_id="B4" value="172.0" spread="8.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Observed Plasma Concentration)</title>
        <description>Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Cmax was obtained directly from experimental observations.</description>
        <time_frame>Up to 72 hours</time_frame>
        <population>The study was designed to evaluate the potential bexagliflozin drug interactions. Study participants were dosed with bexagliflozin alone, other drug alone or both drugs sequentially. The pharmacokinetic parameters were calculated based on the specific analyte using samples collected after dosing of the drug. Therefore, not all samples were analyzed for all outcome measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Bexagliflozin Alone</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Metformin Alone</title>
            <description>Metformin: Metformin tablets, 1000 mg</description>
          </group>
          <group group_id="O3">
            <title>Group 1: Bexagliflozin + Metformin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Metformin: Metformin tablets, 1000 mg</description>
          </group>
          <group group_id="O4">
            <title>Group 2: Bexagliflozin Alone</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
          </group>
          <group group_id="O5">
            <title>Group 2: Glimepiride Alone</title>
            <description>Glimepiride: Glimepiride tablets, 2 mg</description>
          </group>
          <group group_id="O6">
            <title>Group 2: Bexagliflozin + Glimepiride</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Glimepiride: Glimepiride tablets, 2 mg</description>
          </group>
          <group group_id="O7">
            <title>Group 3: Bexagliflozin Alone</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
          </group>
          <group group_id="O8">
            <title>Group 3: Sitagliptin Alone</title>
            <description>Sitagliptin: Sitagliptin tablets, 100 mg</description>
          </group>
          <group group_id="O9">
            <title>Group 3: Bexagliflozin + Sitagliptin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Sitagliptin: Sitagliptin tablets, 100 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Observed Plasma Concentration)</title>
          <description>Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Cmax was obtained directly from experimental observations.</description>
          <population>The study was designed to evaluate the potential bexagliflozin drug interactions. Study participants were dosed with bexagliflozin alone, other drug alone or both drugs sequentially. The pharmacokinetic parameters were calculated based on the specific analyte using samples collected after dosing of the drug. Therefore, not all samples were analyzed for all outcome measurements.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bexagliflozin PK parameters</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.6" spread="43.7"/>
                    <measurement group_id="O3" value="135.5" spread="40.0"/>
                    <measurement group_id="O4" value="158.6" spread="53.9"/>
                    <measurement group_id="O6" value="143.7" spread="37.9"/>
                    <measurement group_id="O7" value="117.1" spread="34.6"/>
                    <measurement group_id="O9" value="148.3" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin PK parameters</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2067.6" spread="27.2"/>
                    <measurement group_id="O3" value="1965.2" spread="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glimepiride PK parameters</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="59.9" spread="32.2"/>
                    <measurement group_id="O6" value="67.1" spread="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitagliptin PK parameters</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O8" value="356.6" spread="22.3"/>
                    <measurement group_id="O9" value="351.2" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric Least Square (LS) Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%</non_inferiority_desc>
            <param_type>Ratio of Geometric LSM</param_type>
            <param_value>108.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.35</ci_lower_limit>
            <ci_upper_limit>125.30</ci_upper_limit>
            <estimate_desc>Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%</non_inferiority_desc>
            <param_type>Ratio of Geometric LSM</param_type>
            <param_value>95.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.73</ci_lower_limit>
            <ci_upper_limit>106.63</ci_upper_limit>
            <estimate_desc>Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%</non_inferiority_desc>
            <param_type>Ratio of Geometric LSM</param_type>
            <param_value>89.44</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>70.39</ci_lower_limit>
            <ci_upper_limit>113.65</ci_upper_limit>
            <estimate_desc>Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%</non_inferiority_desc>
            <param_type>Ratio of Geometric LSM</param_type>
            <param_value>111.95</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.02</ci_lower_limit>
            <ci_upper_limit>129.19</ci_upper_limit>
            <estimate_desc>Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%</non_inferiority_desc>
            <param_type>Ratio of Geometric LSM</param_type>
            <param_value>126.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>112.08</ci_lower_limit>
            <ci_upper_limit>143.17</ci_upper_limit>
            <estimate_desc>Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%</non_inferiority_desc>
            <param_type>Ratio of Geometric LSM</param_type>
            <param_value>98.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.90</ci_lower_limit>
            <ci_upper_limit>114.23</ci_upper_limit>
            <estimate_desc>Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax (Time of Maximum Observed Plasma Concentration)</title>
        <description>Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Tmax was obtained directly from experimental observations.</description>
        <time_frame>Up to 72 hours</time_frame>
        <population>The study was designed to evaluate the potential bexagliflozin drug interactions. Study participants were dosed with bexagliflozin alone, other drug alone or both drugs sequentially. The pharmacokinetic parameters were calculated based on the specific analyte using samples collected after dosing of the drug. Therefore, not all samples were analyzed for all outcome measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Bexagliflozin Alone</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Metformin Alone</title>
            <description>Metformin: Metformin tablets, 1000 mg</description>
          </group>
          <group group_id="O3">
            <title>Group 1: Bexagliflozin + Metformin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Metformin: Metformin tablets, 1000 mg</description>
          </group>
          <group group_id="O4">
            <title>Group 2: Bexagliflozin Alone</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
          </group>
          <group group_id="O5">
            <title>Group 2: Glimepiride Alone</title>
            <description>Glimepiride: Glimepiride tablets, 2 mg</description>
          </group>
          <group group_id="O6">
            <title>Group 2: Bexagliflozin + Glimepiride</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Glimepiride: Glimepiride tablets, 2 mg</description>
          </group>
          <group group_id="O7">
            <title>Group 3: Bexagliflozin Alone</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
          </group>
          <group group_id="O8">
            <title>Group 3: Sitagliptin Alone</title>
            <description>Sitagliptin: Sitagliptin tablets, 100 mg</description>
          </group>
          <group group_id="O9">
            <title>Group 3: Bexagliflozin + Sitagliptin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Sitagliptin: Sitagliptin tablets, 100 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (Time of Maximum Observed Plasma Concentration)</title>
          <description>Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Tmax was obtained directly from experimental observations.</description>
          <population>The study was designed to evaluate the potential bexagliflozin drug interactions. Study participants were dosed with bexagliflozin alone, other drug alone or both drugs sequentially. The pharmacokinetic parameters were calculated based on the specific analyte using samples collected after dosing of the drug. Therefore, not all samples were analyzed for all outcome measurements.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bexagliflozin PK parameters</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O4" value="8.0" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="O6" value="6.0" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="O7" value="3.0" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O9" value="4.0" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin PK parameters</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.5" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glimepiride PK parameters</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="5.5" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O6" value="7.0" lower_limit="1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitagliptin PK parameters</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O8" value="2.5" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O9" value="2.5" lower_limit="1" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1/2 (Apparent Terminal Elimination Half-life)</title>
        <description>Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. T1/2 was obtained directly from experimental observations.</description>
        <time_frame>Up to 72 hours</time_frame>
        <population>The study was designed to evaluate the potential bexagliflozin drug interactions. Study participants were dosed with bexagliflozin alone, other drug alone or both drugs sequentially. The pharmacokinetic parameters were calculated based on the specific analyte using samples collected after dosing of the drug. Therefore, not all samples were analyzed for all outcome measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Bexagliflozin Alone</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Metformin Alone</title>
            <description>Metformin: Metformin tablets, 1000 mg</description>
          </group>
          <group group_id="O3">
            <title>Group 1: Bexagliflozin + Metformin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Metformin: Metformin tablets, 1000 mg</description>
          </group>
          <group group_id="O4">
            <title>Group 2: Bexagliflozin Alone</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
          </group>
          <group group_id="O5">
            <title>Group 2: Glimepiride Alone</title>
            <description>Glimepiride: Glimepiride tablets, 4 mg</description>
          </group>
          <group group_id="O6">
            <title>Group 2: Bexagliflozin + Glimepiride</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Glimepiride: Glimepiride tablets, 4 mg</description>
          </group>
          <group group_id="O7">
            <title>Group 3: Bexagliflozin Alone</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
          </group>
          <group group_id="O8">
            <title>Group 3: Sitagliptin Alone</title>
            <description>Sitagliptin: Sitagliptin tablets, 100 mg</description>
          </group>
          <group group_id="O9">
            <title>Group 3: Bexagliflozin + Sitagliptin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Sitagliptin: Sitagliptin tablets, 100 mg</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 (Apparent Terminal Elimination Half-life)</title>
          <description>Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. T1/2 was obtained directly from experimental observations.</description>
          <population>The study was designed to evaluate the potential bexagliflozin drug interactions. Study participants were dosed with bexagliflozin alone, other drug alone or both drugs sequentially. The pharmacokinetic parameters were calculated based on the specific analyte using samples collected after dosing of the drug. Therefore, not all samples were analyzed for all outcome measurements.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="17"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bexagliflozin PK parameters</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="17"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="30.4"/>
                    <measurement group_id="O3" value="7.8" spread="48.6"/>
                    <measurement group_id="O4" value="8.0" spread="33.3"/>
                    <measurement group_id="O6" value="7.8" spread="34.4"/>
                    <measurement group_id="O7" value="12.6" spread="48"/>
                    <measurement group_id="O9" value="13.3" spread="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin PK parameters</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="9.0" spread="31.8"/>
                    <measurement group_id="O3" value="10.2" spread="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glimepiride PK parameters</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="7.8" spread="46.8"/>
                    <measurement group_id="O6" value="6.6" spread="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitagliptin PK parameters</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O8" value="14.3" spread="22.3"/>
                    <measurement group_id="O9" value="14.8" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)</title>
        <description>Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. AUC0-inf was estimated for each subject.</description>
        <time_frame>Up to 72 hours</time_frame>
        <population>The study was designed to evaluate the potential bexagliflozin drug interactions. Study participants were dosed with bexagliflozin alone, other drug alone or both drugs sequentially. The pharmacokinetic parameters were calculated based on the specific analyte using samples collected after dosing of the drug. Therefore, not all samples were analyzed for all outcome measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Bexagliflozin Alone</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Metformin Alone</title>
            <description>Metformin: Metformin tablets, 1000 mg</description>
          </group>
          <group group_id="O3">
            <title>Group 1: Bexagliflozin + Metformin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Metformin: Metformin tablets, 1000 mg</description>
          </group>
          <group group_id="O4">
            <title>Group 2: Bexagliflozin Alone</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
          </group>
          <group group_id="O5">
            <title>Group 2: Glimepiride Alone</title>
            <description>Glimepiride: Glimepiride tablets, 2 mg</description>
          </group>
          <group group_id="O6">
            <title>Group 2: Bexagliflozin + Glimepiride</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Glimepiride: Glimepiride tablets, 2 mg</description>
          </group>
          <group group_id="O7">
            <title>Group 3: Bexagliflozin Alone</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
          </group>
          <group group_id="O8">
            <title>Group 3: Sitagliptin Alone</title>
            <description>Sitagliptin: Sitagliptin tablets, 100 mg</description>
          </group>
          <group group_id="O9">
            <title>Group 3: Bexagliflozin + Sitagliptin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Sitagliptin: Sitagliptin tablets, 100 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)</title>
          <description>Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. AUC0-inf was estimated for each subject.</description>
          <population>The study was designed to evaluate the potential bexagliflozin drug interactions. Study participants were dosed with bexagliflozin alone, other drug alone or both drugs sequentially. The pharmacokinetic parameters were calculated based on the specific analyte using samples collected after dosing of the drug. Therefore, not all samples were analyzed for all outcome measurements.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bexagliflozin PK parameters</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1154.4" spread="35.1"/>
                    <measurement group_id="O3" value="1008.6" spread="40.2"/>
                    <measurement group_id="O4" value="1204.9" spread="48.6"/>
                    <measurement group_id="O6" value="1162.2" spread="47.8"/>
                    <measurement group_id="O7" value="1011.8" spread="21.5"/>
                    <measurement group_id="O9" value="1158.1" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin PK parameters</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="13351.9" spread="22.5"/>
                    <measurement group_id="O3" value="13784.6" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glimepiride PK parameters</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="496.1" spread="53.3"/>
                    <measurement group_id="O6" value="633.0" spread="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitagliptin PK parameters</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O8" value="3579.6" spread="14.7"/>
                    <measurement group_id="O9" value="3692.8" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%</non_inferiority_desc>
            <param_type>Ratio of Geometric LSM</param_type>
            <param_value>87.36</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80.02</ci_lower_limit>
            <ci_upper_limit>95.38</ci_upper_limit>
            <estimate_desc>Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%</non_inferiority_desc>
            <param_type>Ratio of Geometric LSM</param_type>
            <param_value>103.24</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.59</ci_lower_limit>
            <ci_upper_limit>112.68</ci_upper_limit>
            <estimate_desc>Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%</non_inferiority_desc>
            <param_type>Ratio of Geometric LSM</param_type>
            <param_value>94.46</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80.34</ci_lower_limit>
            <ci_upper_limit>111.06</ci_upper_limit>
            <estimate_desc>Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%.</non_inferiority_desc>
            <param_type>[Ratio of Geometric LSM]</param_type>
            <param_value>127.19</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>110.33</ci_lower_limit>
            <ci_upper_limit>146.62</ci_upper_limit>
            <estimate_desc>Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%</non_inferiority_desc>
            <param_type>[Ratio of Geometric LSM]</param_type>
            <param_value>113.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>107.61</ci_lower_limit>
            <ci_upper_limit>118.86</ci_upper_limit>
            <estimate_desc>Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%</non_inferiority_desc>
            <param_type>[Ratio of Geometric LSM]</param_type>
            <param_value>103.16</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.30</ci_lower_limit>
            <ci_upper_limit>107.17</ci_upper_limit>
            <other_analysis_desc>Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Glucose Excretion up to 0-72 hr</title>
        <description>Pre-dose urine samples were collected from -12 to 0 h for baseline measurement. Subjects was instructed to empty their bladder prior to dosing. Post-dose urine was collected in 4 batches for Groups 1 and 2 at 0 to 12 h, 12 to 24 h, 24 o 36 h, and 36 to 48 h collections. Post-dose urine was collected in batches for Group 3 at 0 to 12 h, 12 to 24 h, 24 to 36 h, 36 to 48 h, 48 to 60 h and 60 to 72 h.</description>
        <time_frame>up to 0-72 hr</time_frame>
        <population>Only subjects with data in the specific category is analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Bexagliflozin Alone</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Metformin Alone</title>
            <description>Metformin: Metformin tablets, 1000 mg</description>
          </group>
          <group group_id="O3">
            <title>Group 1: Bexagliflozin + Metformin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Metformin: Metformin tablets, 1000 mg</description>
          </group>
          <group group_id="O4">
            <title>Group 2: Bexagliflozin Alone</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
          </group>
          <group group_id="O5">
            <title>Group 2: Glimepiride Alone</title>
            <description>Glimepiride: Glimepiride tablets, 4 mg</description>
          </group>
          <group group_id="O6">
            <title>Group 2: Bexagliflozin + Glimepiride</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Glimepiride: Glimepiride tablets, 4 mg</description>
          </group>
          <group group_id="O7">
            <title>Group 3: Bexagliflozin Alone</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
          </group>
          <group group_id="O8">
            <title>Group 3: Sitagliptin Alone</title>
            <description>Sitagliptin: Sitagliptin tablets, 100 mg</description>
          </group>
          <group group_id="O9">
            <title>Group 3: Bexagliflozin + Sitagliptin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Sitagliptin: Sitagliptin tablets, 100 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Glucose Excretion up to 0-72 hr</title>
          <description>Pre-dose urine samples were collected from -12 to 0 h for baseline measurement. Subjects was instructed to empty their bladder prior to dosing. Post-dose urine was collected in 4 batches for Groups 1 and 2 at 0 to 12 h, 12 to 24 h, 24 o 36 h, and 36 to 48 h collections. Post-dose urine was collected in batches for Group 3 at 0 to 12 h, 12 to 24 h, 24 to 36 h, 36 to 48 h, 48 to 60 h and 60 to 72 h.</description>
          <population>Only subjects with data in the specific category is analyzed</population>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 - 12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="12"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.57" spread="8.06"/>
                    <measurement group_id="O2" value="0.02" spread="0.01"/>
                    <measurement group_id="O3" value="26.26" spread="8.86"/>
                    <measurement group_id="O4" value="36.99" spread="14.24"/>
                    <measurement group_id="O5" value="1.26" spread="4.37"/>
                    <measurement group_id="O6" value="31.02" spread="11.19"/>
                    <measurement group_id="O7" value="29.01" spread="6.84"/>
                    <measurement group_id="O8" value="0.03" spread="0.01"/>
                    <measurement group_id="O9" value="23.94" spread="7.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 - 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.32" spread="11.81"/>
                    <measurement group_id="O2" value="0.04" spread="0.03"/>
                    <measurement group_id="O3" value="22.57" spread="8.29"/>
                    <measurement group_id="O4" value="26.85" spread="9.51"/>
                    <measurement group_id="O5" value="0.04" spread="0.05"/>
                    <measurement group_id="O6" value="22.59" spread="11.15"/>
                    <measurement group_id="O7" value="24.38" spread="7.92"/>
                    <measurement group_id="O8" value="0.04" spread="0.05"/>
                    <measurement group_id="O9" value="22.85" spread="9.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 - 36 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="15"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.94" spread="9.16"/>
                    <measurement group_id="O2" value="0.04" spread="0.04"/>
                    <measurement group_id="O3" value="19.50" spread="8.94"/>
                    <measurement group_id="O4" value="29.79" spread="10.24"/>
                    <measurement group_id="O5" value="0.20" spread="0.42"/>
                    <measurement group_id="O6" value="28.46" spread="11.37"/>
                    <measurement group_id="O7" value="22.31" spread="8.97"/>
                    <measurement group_id="O8" value="0.17" spread="0.56"/>
                    <measurement group_id="O9" value="24.15" spread="9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 - 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="17"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.91" spread="4.97"/>
                    <measurement group_id="O2" value="0.02" spread="0.01"/>
                    <measurement group_id="O3" value="5.53" spread="4.17"/>
                    <measurement group_id="O4" value="11.03" spread="7.84"/>
                    <measurement group_id="O5" value="0.03" spread="0.01"/>
                    <measurement group_id="O6" value="9.34" spread="7.55"/>
                    <measurement group_id="O7" value="9.83" spread="6.67"/>
                    <measurement group_id="O8" value="0.03" spread="0.01"/>
                    <measurement group_id="O9" value="10.17" spread="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 - 60 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="15"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="11.32" spread="8.09"/>
                    <measurement group_id="O8" value="0.05" spread="0.07"/>
                    <measurement group_id="O9" value="11.50" spread="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 - 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="17"/>
                    <count group_id="O8" value="17"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="2.67" spread="3.55"/>
                    <measurement group_id="O8" value="0.02" spread="0.01"/>
                    <measurement group_id="O9" value="2.70" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event collection began on the first clinical admission day (Day 0) and continued through D17. The subjects were actively monitored for serious adverse events for at least 14 days after discharge from the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Bexagliflozin Alone</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
        </group>
        <group group_id="E2">
          <title>Group 1: Metformin Alone</title>
          <description>Metformin: Metformin tablets, 1000 mg</description>
        </group>
        <group group_id="E3">
          <title>Group 1: Bexagliflozin + Metformin</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Metformin: Metformin tablets, 1000 mg</description>
        </group>
        <group group_id="E4">
          <title>Group 2: Bexagliflozin Alone</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
        </group>
        <group group_id="E5">
          <title>Group 2: Glimepiride Alone</title>
          <description>Glimepiride: Glimepiride tablets, 2 mg</description>
        </group>
        <group group_id="E6">
          <title>Group 2: Bexagliflozin + Glimepiride</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Glimepiride: Glimepiride tablets, 2 mg</description>
        </group>
        <group group_id="E7">
          <title>Group 3: Bexagliflozin Alone</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg</description>
        </group>
        <group group_id="E8">
          <title>Group 3: Sitagliptin Alone</title>
          <description>Sitagliptin: Sitagliptin tablets, 100 mg</description>
        </group>
        <group group_id="E9">
          <title>Group 3: Bexagliflozin + Sitagliptin</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg&#xD;
Sitagliptin: Sitagliptin tablets, 100 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Puncture site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Puncture site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Catheter site induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Swelling of face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Program Director</name_or_title>
      <organization>Translational Medicine Group</organization>
      <phone>617-726-4236</phone>
      <email>yhalvorsen@ccib.mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

